Delayed recovery of homogeneous perfusion distribution in isolated rat heart after vasodilatation induced by alpha 1 adrenoceptor blockade during postischaemic reperfusion. 1989

R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
Department of Cardiology, University Hospital, Leiden, The Netherlands.

The purpose of this study was to investigate whether vasodilatation induced by doxazosin, an alpha 1 adrenoceptor blocker, during postischaemic reperfusion was able to accelerate reflow in unperfused myocardium. Isolated isovolumetrically beating rat hearts were exposed to global ischaemia by perfusion at 15 mm Hg for 2 h, resulting in an end ischaemic coronary flow rate of 2.3 (SD 1.7)% of preischaemic value, and an unperfused myocardial volume of 71.8(4.3)% of total myocardial volume. Subsequent reperfusion at 80 mm Hg for 2 h produced a partial recovery of coronary flow rate of 41(6)% in the absence of doxazosin and a complete recovery [97(28)%] in the presence of doxazosin 2 mumol.litre-1. Surprisingly, doxazosin induced vasodilatation retarded the disappearance of "no reflow" during reperfusion: after 3 h of reperfusion the volume of unperfused myocardium was 14.3(5.5)% v 1.5(1.7)% in the control group (p less than 0.005). Assessed histologically the regions of "no-reflow" were localised predominantly in the subendocardium. In the presence of doxazosin, left ventricular end diastolic pressure during reperfusion was twice as high as in the control group, indicating pronounced subendocardial compression. The mechanism underlying prolonged subendocardial "no-reflow" in the presence of doxazosin during postischaemic reperfusion is a compressive action of dilated (sub)epicardial vessels on the vasculature in the unperfused subendocardial regions ("hydraulic" or "erectile" effect of increased vascular volume). Thus coronary vasodilatation induced by alpha 1 adrenergic receptor blockade during postischaemic reperfusion delays the recovery of homogeneous transmural perfusion distribution.

UI MeSH Term Description Entries
D007770 L-Lactate Dehydrogenase A tetrameric enzyme that, along with the coenzyme NAD+, catalyzes the interconversion of LACTATE and PYRUVATE. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist. Lactate Dehydrogenase,Dehydrogenase, L-Lactate,Dehydrogenase, Lactate,L Lactate Dehydrogenase
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D001783 Blood Flow Velocity A value equal to the total volume flow divided by the cross-sectional area of the vascular bed. Blood Flow Velocities,Flow Velocities, Blood,Flow Velocity, Blood,Velocities, Blood Flow,Velocity, Blood Flow
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013318 Stroke Volume The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume. Ventricular Ejection Fraction,Ventricular End-Diastolic Volume,Ventricular End-Systolic Volume,Ejection Fraction, Ventricular,Ejection Fractions, Ventricular,End-Diastolic Volume, Ventricular,End-Diastolic Volumes, Ventricular,End-Systolic Volume, Ventricular,End-Systolic Volumes, Ventricular,Fraction, Ventricular Ejection,Fractions, Ventricular Ejection,Stroke Volumes,Ventricular Ejection Fractions,Ventricular End Diastolic Volume,Ventricular End Systolic Volume,Ventricular End-Diastolic Volumes,Ventricular End-Systolic Volumes,Volume, Stroke,Volume, Ventricular End-Diastolic,Volume, Ventricular End-Systolic,Volumes, Stroke,Volumes, Ventricular End-Diastolic,Volumes, Ventricular End-Systolic
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator

Related Publications

R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
May 1995, British journal of pharmacology,
R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
February 1989, British journal of pharmacology,
R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
January 1988, Archives internationales de pharmacodynamie et de therapie,
R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
May 1994, Journal of molecular and cellular cardiology,
R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
April 1985, Journal of molecular and cellular cardiology,
R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
April 1991, Cardiovascular research,
R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
June 1981, European journal of pharmacology,
R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
July 1992, Cardiovascular research,
R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
May 1990, European journal of pharmacology,
R W Mohanlal, and I Mauve, and L van der Valk, and A V Bruschke, and A van der Laarse
July 1987, Cardiovascular research,
Copied contents to your clipboard!